L. to r.: Dr. J.-C. Tardif, Director, MHI-RI, Dr. J. Turgeon, Director, CHUM Research Centre, Mr. C. Schiever, Pres. and Managing Director, Merck Canada, Dr. V. Papadopoulos, Exec. Director, RI-MUHC and Mr. M. LeBlanc, Vice-Chairman of the Board, Montréal InVivo.

November 26, 2012 – Merck Canada announced today that it is reinforcing its commitment to growing Montréal’s life sciences basic and translational research sector, by investing $12.5 million to fund research at three prominent university-affiliated and hospital-based research centres. This investment marks the latest contribution by Merck in its 2010 announcement to inject $100 million over five years in biopharmaceutical research and development (R&D) in Québec.

This investment by Merck supports the Research Institute of the McGill University Health Centre (RI-MUHC), the CHUM Research Centre (CRCHUM) and the Montréal Heart Institute Research Centre (MHI), and their mission of promoting the development of scientific advancements that will improve healthcare.

Read the full story on the MUHC’s website.

December 5, 2012